Journal profile · Virology
Antiviral Therapy
ISSN 1359-6535 · eISSN 2040-2058 · International Medical Press Ltd · ENGLAND · Bimonthly · Founded 1996
Antiviral Therapy: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 3.21; fully open access; APC about USD 2,800; review 4–8 weeks (community reports); community-reported acceptance: fairly hard; 18 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Antiviral Therapy is published by International Medical Press Ltd and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are HIV/AIDS drug development and treatment, HIV Research and Treatment and Hepatitis C virus research, together about 48.9% of its articles. Its main subfields are Epidemiology. (generated from OpenAlex topic counts and CAS ranking data)
Antiviral Therapy is an international, peer-reviewed journal devoted to publishing articles on the clinical development and use of antiviral agents and vaccines, and the treatment of all viral diseases. Antiviral Therapy is one of the leading … | View full journal description
From the journal's Aims & Scope
Research area (LetPub): Virology
Editor-in-chief Katharine J. BarPublisher website
Editorial board by country: 1 in mainland China (about 2%); most named United States 21, United Kingdom 6, France 5, Germany 3, Canada 3 (55 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- HIV/AIDS drug development and treatmentMedicine21.3%
- HIV Research and TreatmentImmunology and Microbiology15%
- Hepatitis C virus researchMedicine12.6%
- HIV-related health complications and treatmentsMedicine11.2%
- HIV/AIDS Research and InterventionsMedicine10.2%
- Hepatitis B Virus StudiesMedicine8.3%
- Liver Disease Diagnosis and TreatmentMedicine3%
- Hepatitis Viruses Studies and EpidemiologyMedicine2.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Infectious Diseases | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
| Minor | Virology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Infectious Diseases | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
| Minor | Virology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Infectious Diseases | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
| Minor | Virology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.21LetPub ·
- Impact factor (publisher)
- 3.3Publisher website ·
- 5-year impact factor (publisher)
- 2.1Publisher website ·
- CiteScore 2026-06
- 4.9LetPub ·
- SJR 2026-06
- 0.84LetPub ·
- SNIP 2026-06
- 0.91LetPub ·
- h-index
- 78LetPub ·
- h-index
- 103OpenAlex ·
- i10-index
- 1,698OpenAlex ·
- 2-year mean citedness
- 2.19OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 18LetPub ·
- Articles per year (publisher)
- 3Publisher website ·
Articles by year OpenAlex count · 2,609 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 8 | 8 | 0 |
| 2025 | 18 | 18 | 30 |
| 2024 | 11 | 11 | 51 |
| 2023 | 31 | 31 | 260 |
| 2022 | 39 | 39 | 323 |
| 2021 | 19 | 12 | 86 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- 4–8 weeksLetPub ·
- Average acceptance (community reports)
- Fairly hardLetPub ·
- Submission to publication (journal-reported)
- about 24 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 2,800 | Yes | CC BY, CC BY-NC | |
| OpenAlex | USD 2,800 | — | — | |
| Publisher website | USD 2,000 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare3 items from the author guidelines
- Abstract
- ≤ 250 words
- Manuscript length
- ≤ 4,000 words
- Reference style
- Vancouver
Article types accepted11, with length limits
- case reportView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…main text ≤ 1,500 words
- commentarystructured summary (maximum 100 words). Commentary ≤1,500 words, ≤20 references, ≤2 display items Commentaries are based onmain text ≤ 1,500 words
- full articleView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…Length not stated
- full paperView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…Length not stated
- letterstructured summary (maximum 150 words). Letter ≤1,000 words, ≤15 references, ≤2 display items Letters are articles thatmain text ≤ 1,000 words
- meta-analysisView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…Length not stated
- original articleView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…main text ≤ 4,000 words
- original researchView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…Length not stated
- reviewView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…main text ≤ 5,000 words
- short communicationView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…main text ≤ 1,500 words
- systematic reviewView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…Length not stated
Policy excerpts from the journal's websiteAuthorship, Data availability, Publication ethics, Open access, Peer review, Plagiarism, Preprints, Trial registration / reporting guidelines
- Authorship Authorship
Please view our authorship policies, which includes information on criteria for authorship, who should be the corresponding author and more. Please note that AI chatbots, for example ChatGPT, should not be listed as authors. For more information see the policy on Use of ChatGPT and generative AI tools.
Source ↗Publisher website ·- Data availability Data availability
The Journal is committed to facilitating openness, transparency and reproducibility of research, and has the following research data sharing policy. For more information, including FAQs please visit the Sage Research Data policy pages. Subject to appropriate ethical and legal considerations, authors are encouraged to: Share your research data in a relevant public data repository Include a data ava…
Source ↗Publisher website ·- Publication ethics Ethical considerations
Please include your ethics approval statements under this heading, even if you have already included ethics approval information in your methods section. If ethical approval was not required, you need to explicitly state this. All papers reporting studies involving human participants, human data or human tissue must state that the relevant Ethics Committee or Institutional Review Board approved th…
Source ↗Publisher website ·- Open access Publishing fees and open access
Antiviral Therapy is an open access, peer-reviewed journal. All accepted articles are made freely available online immediately upon publication, are published under a Creative Commons license, and hosted online in perpetuity. If, after peer review, your manuscript is accepted for publication, a one-time article processing charge (APC) is payable to cover the cost of publishing, paid by the funder,…
Source ↗Publisher website ·- Peer review Peer review policy
The following summary describes the peer review process for this journal: Identity transparency:Single-anonymized Reviewer interacts with: Editor Review information published: None Your manuscript will undergo an initial evaluation. If it does not conform to the requirements laid out in these guidelines, it will be returned to you for amendments prior to peer review. Manuscripts may be desk reject…
Source ↗Publisher website ·- Plagiarism Plagiarism
The journal and Sage take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. Please read Sage's complete policy on plagiarism and the actions we may take.
Source ↗Publisher website ·- Preprints Preprints
The journal will consider submissions of manuscripts that have been posted on preprint servers. Please enter the preprint DOI in the designated field when submitting your manuscript. We advise that you inform the Journal Editorial office about your posted preprint at submission. Note that you should not post an updated version of your manuscript on a preprint server while it is being peer reviewed…
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical trial registration
The journal conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first participant enrollment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- International Medical Press Ltd
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1996
- ISSN
- 1359-6535
- Electronic ISSN
- 2040-2058
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Antiviral Therapy
What CAS zone is Antiviral Therapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Antiviral Therapy is in Zone 4 of Medicine, and in Zone 4 of the minor category Infectious Diseases / Pharmacology & Pharmacy / Virology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Antiviral Therapy?
The latest impact factor listed by LetPub is 3.21; CiteScore 4.9, h-index 103.
How long does peer review take at Antiviral Therapy?
Authors report an average review time of 4–8 weeks; the community-reported acceptance is “Fairly hard”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Antiviral Therapy?
According to the journal's author guidelines: Abstract: ≤ 250 words; Manuscript length: ≤ 4,000 words; Reference style: Vancouver. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Antiviral Therapy based?
Of the 55 board members whose country the journal's board page names, 1 (about 2%) are in mainland China; the countries named most often are United States (21), United Kingdom (6) and France (5). Counted from the institutions listed on the board page; for reference only.
Which databases index Antiviral Therapy?
According to LetPub and DOAJ records, Antiviral Therapy is indexed in SCIE, Scopus and DOAJ.
Is Antiviral Therapy open access, and what is the APC?
Antiviral Therapy is a fully open-access journal. APC about USD 2,800.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .